Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Therapy Guided by PTC Drug Screening for HER2 Negative Early Breast Cancer
NCT04836156Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Apr 2021
- Primary completion
- Jun 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, carboplatin, epirubicin, cyclophosphamide in breast cancer, sponsored by Peking University People's Hospital. Started Apr 2021; status: recruiting.
02
Drugs
docetaxelcarboplatinepirubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04836156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04836156.